Sanaei Masumeh, Kavoosi Fraidoon, Esmi Zahra
Research Center for Non-communicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran.
Research Committee Student, Jahrom University of Medical Sciences, Jahrom, Iran.
Int J Hematol Oncol Stem Cell Res. 2020 Jan 1;14(1):45-55.
Aberrant methylation and histone deacetylation of tumor suppressor genes (TSGs) are the most epigenetic alterations involving in tumorigenesis. Overexpression of DNA methyltransferases (DNMTs) and histone deacetylase 1 (HDAC1) have been reported in several cancers. The reversion of hypermethylation and deacetylation by epi-drugs such as 5-aza-2'-deoxycytidine (5-AZA-CdR) and vorinostat (SAHA) can restore normal expression of TSGs. Previously, we reported that 5-AZA-CdR and valproic acid (VPA) can inhibit DNMT1 in hepatocellular carcinoma (HCC). The aim of this study was to investigate the effect of 5-AZA-CdR in combination to and in comparison with SAHA on DNMT1, DNMT3a, DNMT3b, histone deacetylase 1 (HDAC1), glutathione S-transferase 1 (GSTP1) and suppressor of cytokine signaling 1 (SOCS1) genes expression, cell growth inhibition and apoptotic induction in hepatocellular LCL-PI 11 cell line. The cells were treated with 5-AZA-CdR and SAHA and then MTT assay, cell apoptosis assay and Real-time quantitative RT-PCR (qRT-PCR) were done. Both agents indicated significant inhibitory and apoptotic effect (P< 0.001). The apoptotic effect of SAHA was more than that of 5-Aza-CdR. The result of qRT-PCR indicated that 5-Aza-CdR decreased DNMT1, DNMT3a, DNMT3b and increased GSTP1and SOCS1 genes expression and SAHA decreased HDAC1 and increased GSTP1 and SOCS1 genes expression significantly. Maximal apoptosis and genes expression were seen with combined treatment. 5-AZA-CdR and SAHA down-regulated DNMT1, DNMT3a, DNMT3b, and HDAC1 and up-regulated GSTP1 and SOCS1 gene expression by which inhibited cell viability and induced apoptosis, suggesting that they could be used in the treatment of HCC.
肿瘤抑制基因(TSGs)的异常甲基化和组蛋白去乙酰化是参与肿瘤发生的最主要表观遗传改变。在几种癌症中已报道了DNA甲基转移酶(DNMTs)和组蛋白去乙酰化酶1(HDAC1)的过表达。5-氮杂-2'-脱氧胞苷(5-AZA-CdR)和伏立诺他(SAHA)等表观遗传药物可逆转高甲基化和去乙酰化,从而恢复TSGs的正常表达。此前,我们报道5-AZA-CdR和丙戊酸(VPA)可抑制肝细胞癌(HCC)中的DNMT1。本研究的目的是研究5-AZA-CdR与SAHA联合使用以及对比单独使用时,对肝细胞LCL-PI 11细胞系中DNMT1、DNMT3a、DNMT3b、组蛋白去乙酰化酶1(HDAC1)、谷胱甘肽S-转移酶1(GSTP1)和细胞因子信号转导抑制因子1(SOCS1)基因表达、细胞生长抑制和凋亡诱导的影响。用5-AZA-CdR和SAHA处理细胞,然后进行MTT试验、细胞凋亡试验和实时定量逆转录聚合酶链反应(qRT-PCR)。两种药物均显示出显著的抑制和凋亡作用(P<0.001)。SAHA的凋亡作用大于5-氮杂胞苷。qRT-PCR结果表明,5-氮杂胞苷降低DNMT1、DNMT3a、DNMT3b的表达并增加GSTP1和SOCS1基因的表达,SAHA显著降低HDAC1的表达并增加GSTP1和SOCS1基因的表达。联合治疗时观察到最大程度的凋亡和基因表达变化。5-AZA-CdR和SAHA下调DNMT1、DNMT3a、DNMT3b和HDAC1的表达,上调GSTP1和SOCS1基因的表达,从而抑制细胞活力并诱导凋亡,表明它们可用于治疗HCC。